Creative Planning Buys 3,979 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Creative Planning grew its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 18.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,925 shares of the company’s stock after buying an additional 3,979 shares during the quarter. Creative Planning’s holdings in Hims & Hers Health were worth $478,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Renaissance Technologies LLC boosted its holdings in Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after purchasing an additional 3,205,108 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after purchasing an additional 1,634,000 shares during the last quarter. M&G Plc purchased a new position in Hims & Hers Health during the first quarter worth about $8,232,000. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Hims & Hers Health by 164.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after purchasing an additional 328,142 shares during the last quarter. Finally, State of Michigan Retirement System boosted its holdings in Hims & Hers Health by 177.8% during the second quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after purchasing an additional 320,000 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $23.16, for a total transaction of $54,171.24. Following the sale, the insider now owns 169,935 shares of the company’s stock, valued at approximately $3,935,694.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Michael Chi sold 7,500 shares of the stock in a transaction on Monday, October 21st. The shares were sold at an average price of $22.20, for a total value of $166,500.00. Following the transaction, the insider now owns 193,980 shares of the company’s stock, valued at $4,306,356. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 2,339 shares of the stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the transaction, the insider now directly owns 169,935 shares in the company, valued at $3,935,694.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 650,659 shares of company stock valued at $11,712,198. Company insiders own 17.71% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday. TD Cowen boosted their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Truist Financial boosted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Hims & Hers Health Stock Up 13.6 %

NYSE HIMS opened at $23.44 on Thursday. The company’s 50 day moving average is $18.22 and its 200-day moving average is $18.26. Hims & Hers Health, Inc. has a 12-month low of $6.58 and a 12-month high of $25.74. The firm has a market cap of $5.03 billion, a P/E ratio of 53.27 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. Hims & Hers Health’s revenue was up 77.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.04) EPS. Equities analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.